JOHN KIRKWOOD to Drug-Related Side Effects and Adverse Reactions
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Drug-Related Side Effects and Adverse Reactions.
Connection Strength
0.991
-
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
Score: 0.568
-
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients. Clin Cancer Res. 2025 Dec 01; 31(23):5027-5036.
Score: 0.195
-
Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
Score: 0.134
-
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013 Apr; 24(4):1112-9.
Score: 0.079
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81.
Score: 0.015